You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Responsible Drinking: Internet-based, Interactive Computer Tailored Intervention

    SBC: Pro-Change Behavior Systems Inc            Topic: NIAAA

    DESCRIPTION (provided by applicant): Excessive alcohol use is associated with a range of serious and costly health, social, and economic consequences at the individual and societal level. This program of research serves as a venue by which to produce and test an innovative, science-based, and cost-effective means to intervene in a private, convenient, and individualized way with employed adults wh ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  2. RAIL reduces variability and concentration of stress hormones in blood sampling

    SBC: ACTUATED MEDICAL, INC.            Topic: NIA

    DESCRIPTION (provided by applicant): In this Phase II SBIR, Actuated Medical, Inc. (f/k/a Piezo Resonance Innovations, Inc) will complete the development of the Resonance Assisted Insertion Lancet (RAIL ) System to reduce animal pain and stress response during laboratory animal blood sampling. Public Health Problem: Understanding the physiological and biological mechanisms of aging is the focus o ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  3. Defining T cell epitopes in Dengue virus infection

    SBC: IMMUNOTOPE, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): There is a well-recognized need to develop vaccines that stimulates humoral immunity as well as a potent T cell immunity in order to achieve protection from infection with pathogens. Although numerous investigations arefocused on developing vaccines that induce protective humoral responses, only a few studies are aimed towards developing specific T cell immunit ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  4. Portable electronically controlled transdermal patch for enfuvirtide delivery

    SBC: ACTUATED MEDICAL, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): In this Phase II NIH SBIR, Piezo Resonance Innovations will further optimize and test the Portable Transdermal Patch (PTP) - a needle-free platform delivery technology for drugs and vaccines that are currently deliveredsubcutaneously. The portable, 200gm (7oz) electronically-controlled transdermal patch for Enfuvirtide delivery employs a patented transducer tec ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  5. Development of Small Antimicrobial Peptide Mimics as Drug-Resistant and Susceptib

    SBC: PolyMedix, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Malaria is a global disease causing gt 500 million clinical cases and gt 1 million deaths each year. Moreover, drug resistant Plasmodium falciparum has become a major problem. Therefore, it is crucial to discover new classes of drugs for anti-malarial drug design to combat resistant parasites. We propose that antimicrobial peptides (AMPs) may provide the basis ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  6. Computerized Stage-Matched Intervention for Juvenile Offenders

    SBC: Pro-Change Behavior Systems Inc            Topic: NIDA

    DESCRIPTION (provided by applicant): Juvenile crime imposes enormous costs on victims, on society, and on juvenile offenders themselves. However, research assessing the efficacy of interventions for young offenders show, on average, only small effects on recidivism, substance abuse, and other behavioral outcomes. A major problem with existing interventions is that they tend to neglect individual d ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  7. EpiVax Phase II SBIR: Preclinical studies of Tregitope Delivery and Mechanism of

    SBC: EPIVAX, INC.            Topic: NIDDK

    DESCRIPTION (provided by applicant): The goal of this Phase II project is to advance the development of novel tolerance-inducing peptides (Tregitopes) to prevent and/or treat Type 1 diabetes (T1D) by optimizing the clinical delivery vehicle and treatment protocol, and by identifying correlates of efficacy in preparation for Phase 1 clinical trials. More than 13,000 children in the U.S. are diagnos ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  8. A novel fluorescent assay for ubiquitin isopeptide bond cleavage

    SBC: LIFESENSORS, INC.            Topic: NIGMS

    DESCRIPTION (provided by applicant): In the last decade there has been an explosive growth in the field of ubiquitin research, with approximately 530 human genes predicted to encode enzymes involved in the conjugation and deconjugation of ubiquitin. Of these 95 encode for deubiquitylases (DUBs). In order understand the biology of these enzymes better, there is a need for better assays to measure t ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  9. Research and Deployment of a quantum mechanical NMR tool for fragment based drug

    SBC: QuantumBio, Inc.            Topic: NIGMS

    DESCRIPTION (provided by applicant): Improving human health by enabling the development of drugs faster and cheaper is an important part of the NIH mission. This is partially achieved by introducing and constantly improving enabling technologies. One suchtechnology is structure based drug design. Determining the structure of a small molecule (drug candidate or lead compound) to a biological recept ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  10. Novel Modulators of HDL Metabolism

    SBC: Shifa Biomedical Corporation            Topic: NHLBI

    Project Summary/Abstract Cardiovascular disease remains the leading cause of morbidity and mortality for both men and women, accounting for nearly 40% of annual deaths. High levels of LDL-C and low levels of HDL-C are well-known risk factors for heart disease. Although lowering low-density lipoprotein cholesterol (LDL-C) levels using a number of marketed drugs, of which statins are the leading dr ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government